Does RELUGOLIX Cause Malignant neoplasm progression? 12 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Malignant neoplasm progression have been filed in association with RELUGOLIX (Orgovyx). This represents 0.1% of all adverse event reports for RELUGOLIX.
12
Reports of Malignant neoplasm progression with RELUGOLIX
0.1%
of all RELUGOLIX reports
1
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RELUGOLIX?
Of the 12 reports, 1 (8.3%) resulted in death.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RELUGOLIX. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does RELUGOLIX Cause?
Hot flush (6,845)
Fatigue (5,203)
Therapy interrupted (3,251)
Incorrect dose administered (1,917)
Asthenia (1,718)
Arthralgia (1,385)
Diarrhoea (1,383)
Product dose omission issue (1,189)
Dizziness (1,146)
Constipation (902)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RELUGOLIX Alternatives Have Lower Malignant neoplasm progression Risk?
RELUGOLIX vs REMDESIVIR
RELUGOLIX vs REMERON
RELUGOLIX vs REMICADE
RELUGOLIX vs REMIFENTANIL
RELUGOLIX vs REMIMAZOLAM